Mark Fortner

Pancreatic Cancer and the Microbiome

Beyond the genomic complexity of the disease, we’ve begun to examine the effect of the microbiome on pancreatic cancer. In a recent paper in Science, “Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine” [Geller et al] reported that 76% of pancreatic cancer patients in their study (n=113) had gammaproteobacteria in

Pancreatic Cancer and the Microbiome Read More »

Subtypes of Pancreatic Cancer

In the third part of this series on pancreatic cancer, we’ll take a look at recent developments in identifying subtypes of pancreatic cancer and its potential impact on the lives of pancreatic cancer patients. Twenty-one years ago, we had identified some of the histologically distinct types of pancreatic cancer. These neoplastic tissue types included: PanINs

Subtypes of Pancreatic Cancer Read More »

The Genetics of Pancreatic Cancer

In the second part of this series on pancreatic cancer, we’ll look at the changes in our understanding of the role of familial genetics in pancreatic cancer, and how that new understanding holds promise for new therapeutics. In the mid-1970s doctors began reporting cases of familial pancreatic cancer, where multiple first-degree relatives had presented with

The Genetics of Pancreatic Cancer Read More »

Exchanging Drug Pipeline Data

The pharmaceutical R&D environment has always been collaborative in nature — never moreso today. Key to the success of those collaborations is the ability to share information about drug R&D programs with a wide variety of potential partners and investors. Traditionally pharmaceutical companies rely on expensive databases to identify potential partners. These databases usually do a

Exchanging Drug Pipeline Data Read More »

Scroll to Top